Prof Xavier Leleu speaks to ecancer about the BENEFIT study.

This study evaluated the added value of isatuximab plus lenalidomide and dexamethasone with bortezomib compared to isatuximab plus lenalidomide and dexamethasone.

The primary endpoint of this study was minimal residual disease negative rate at 10-5 by next-generation sequencing at 18 months from randomisation.

The results showed that isatuximab plus lenalidomide and dexamethasone with bortezomib significantly increased MRD endpoints, including the 18-month negative rate at 10-5, the primary endpoint, compared to isatuximab plus lenalidomide and dexamethasone.